Indeed, exogenous p21 greatly reduced IFN-γ and IL-17 overexpression by these cells, which is linked to hyperresponsiveness51, suggesting that p21 regulation of T cell activity could be used in therapeutic design for ALPS patients. The gene discussed is CDKN1A; the disease is autoimmune lymphoproliferative syndrome.